Cloud Banner

Press Release

Jul, 31 2023

Transforming Warts: Innovative Solutions for Effective Treatment

A total of 42.5 million people in the U.S. were infected with HPV in 2018, and it has been estimated that 20% of the population suffers from STIs. There are more than 60 different types of HPV, some of which are known to lead to skin warts. Cryotherapy involves freezing the wart using liquid nitrogen. It is commonly used for the treatment of warts on the hands, feet, or other parts of the body. The freezing process destroys the wart tissue, and the wart eventually falls off. Additionally, Over-the-counter and prescription topical medications, such as salicylic acid, can be used for the treatment of common warts. These medications help remove the wart gradually by causing peeling or erosion of the skin.

Access full Report @ https://www.databridgemarketresearch.com/reports/us-warts-treatment-market

Data Bridge Market Research analyses that the U.S. Warts Treatment Market tends to be around 8.70% in the mentioned forecast period from 2023 to 2030. The market value is USD 530.7 million in 2022 and it would grow up to USD 1034.3 million by 2030. There is a growing demand for non-invasive treatment options among patients, as they offer minimal pain, shorter recovery periods, and reduced scarring. Non-invasive treatments such as topical creams, gels, and solutions are preferred by individuals seeking effective wart removal solutions without undergoing surgical procedures.

Key Findings of the Study

U.S. Warts Treatment Market

Increased research and development activities are expected to drive the market's growth rate

During the forecast period, it is anticipated that increased R&D to develop treatments for warts will accelerate market growth. For instance, on March 21 a collaboration and license agreement was signed by Verrica Pharmaceuticals Inc. and Torii Pharmaceutical Co., Ltd. to develop and market product candidates, including VP-102, a topical cantharidin formulation for the treatment of molluscum contagiosum and common warts. Submitting an IND request to the US FDA for the new product candidate SB207, Novan improved its proprietary product pipeline for external genital warts in October 2019. Thus, the market is growing as a result of all these developments.

Report Scope and Market Segmentation

Report Metric

Details

Forecast Period

2023 to 2030

Base Year

2022

Historic Years

2021 (Customizable to 2015-2020)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

Type (Common Warts (Verruca Vulgaris), Genital Warts, Plantar Warts, Flat Warts, Filiform Warts, Periungual Warts, Others), Treatment (Medication, Therapy, Laser Treatment, Surgery,  Cantharidin, Candida Antigen Shots, Acupuncture, Others), Product (Prescription, Over the Counter (OTC)), Dosage Form (Creams, Liquid, Gels, Injectable Solutions, Pads, Tape, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)

Market Players Covered

Bausch Health Companies Inc (Canada), Merck & Co., Inc (U.S.), Taro Pharmaceutical Industries Ltd (Israel), CryoIQ (Sweden), GSK plc (U.K.), BioNTech SE (Germany), Serum Institute of India Pvt. Ltd (India), Fotona (U.S.), Orgenesis Inc (U.S.), Perrigo Company plc (Ireland), CryoSurgery, Inc (U.S.), Bristol-Myers Squibb Company (U.S.), Nielsen Biosciences (U.S.), Verrica Pharmaceuticals (U.S.), Aclaris Therapeutics, Inc (U.S.), Nowarta Biopharma Inc. (U.S.), Novan, Inc. (U.S.), Vaxart (U.S.)

Data Points Covered in the Report

In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Segment Analysis:

The U.S. warts treatment market is segmented on the basis of type, treatment, product, dosage form, end user, and distribution channel.

  • On the basis of type, the U.S. Warts treatment market is segmented into common warts (verruca vulgaris), genital warts, plantar warts, flat warts, filiform warts, periungual warts, and others. Common warts (verruca vulgaris) segment is dominating the type segment of the market with the market share of 43.6% and growing in the forecast period of 2023-2030 due to their prevalence, ease of transmission, and the availability of various treatment options, including medications, cryotherapy, and topical applications, catering to diverse patient needs.

In 2023, the common warts (verruca vulgaris) segment is dominating the type segment of the market

In 2023, the common warts (verruca vulgaris) segment is dominating the type segment of the market owing to the They are common, easily spread, and have a variety of treatment options, including medications, cryotherapy, and topical applications, to meet the needs of different patients with the market share of 43.6% and growing in the forecast period of 2023-2030.

  • On the basis of treatment, the U.S. Warts treatment market is segmented  into medication, therapy, laser treatment, surgery, cantharid in, candida antigen shots, acupuncture, others. The medication segment is dominating the treatment segment of the market with the highest CAGR of 9.4% in the forecast period of 2023-2030 due to its widespread availability, ease of use, and effectiveness in eliminating warts, making it the preferred choice for most patients.
  • On the basis of product, the U.S. Warts treatment market is segmented into prescription, over the counter (OTC). The prescription segment is dominating the product segment of the market with a CAGR of 9.5% in the forecast period of 2023-2030 due to their regulated distribution, requiring a healthcare professional's authorization. This ensures safety, effectiveness, and tailored treatment for various conditions, enhancing patient outcomes and minimizing risks associated with self-medication.

In 2023, the Prescription segment is dominating the product segment of the market

In 2023, the Prescription segment is dominating the product segment of the market owing to their controlled distribution, which calls for a doctor's approval. This improves patient outcomes and reduces the risks associated with self-medication while ensuring safety, effectiveness, and tailored treatment for a variety of conditions with a CAGR of 9.5% in the forecast period of 2023-2030

  • On the basis of dosage form, the U.S. Warts treatment market is segmented  into creams, liquid, gels, injectable solutions, pads, tape, others. Creams segment is dominating the dosage form segment of the market with the market share of 46.9% in the forecast period of 2023-2030 due to their versatility, ease of application, and ability to deliver medication directly to the affected area. They are preferred for skin conditions, providing localized treatment, moisturization, and compatibility with various skin types.
  • On the basis of end-users, the U.S. Warts treatment market is segmented into hospitals, homecare, specialty clinics, and others.
  • On the basis of distribution channel, the U.S. Warts treatment market is segmented into hospital pharmacy, online pharmacy, retail pharmacy. Online pharmacy dominate the distribution channel of the market with a CAGR of 10.4% in the forecast period of 2023-2030 due to convenient access to over-the-counter wart treatments, prescriptions, and home delivery services, offering a hassle-free and discreet way to obtain warts treatment products.

Major Players

Data Bridge Market Research recognizes the following companies as the major U.S. warts treatment market players in U.S. warts treatment market are Bausch Health Companies Inc (Canada), Merck & Co., Inc (U.S.), Verrica Pharmaceuticals (U.S.), Verrica Pharmaceuticals (U.S.), Nielsen Biosciences (U.S.)

U.S. Warts Treatment Market

Market Development

  • In 2021, The first generic Absorica (isotretinoin) pills were made available by Teva Pharmaceuticals to treat severe recalcitrant nodular acne warts. For people with resistant facial plane warts, oral isotretinoin is an effective treatment option.
  • In 2020, Tamir Biotechnology, Inc. was purchased by Orgenesis Inc., along with Tamir Bio's broad-spectrum antiviral platform Ranpirnase. Based on stock valuation at the time of close, the total stock and cash consideration was around USD 21 million.
  • In 2020, Tamir Biotechnology, Inc. was fully acquired by Orgenesis Inc., along with Tamir Bio's broad spectrum antiviral platform Ranpirnase. Total stock and cash consideration was about USD 21 million, based on stock valuation at the time of closure.
  • In 2020, For the treatment of molluscum contagiosum and common warts in Japan, Verrica Pharmaceuticals Inc. and Torii Pharmaceutical Co., Ltd. recently announced a partnership and licensing agreement for the development and marketing of product candidates, including VP-102.
  • In 2020 Ameluz will be developed and marketed for all indications in East Asia and Oceania under an exclusive licensing agreement signed by Bio Frontera AG, a global biopharmaceutical company, and Maruho Co., Ltd., based in Osaka, Japan.

For more detailed information about the U.S. warts treatment market report, click here – https://www.databridgemarketresearch.com/reports/us-warts-treatment-market


Client Testimonials